disufenton sodium has been researched along with Brain Ischemia in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 29 (90.63) | 29.6817 |
| 2010's | 3 (9.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balogh, GT; Fischer, J; Gere, A; Kis-Varga, A; Könczöl, A; Vukics, K | 1 |
| Alcázar, A; Ayuso, MI; Chioua, M; Hadjipavlou-Litina, DJ; Marco-Contelles, J; Martínez-Alonso, E; Masjuán, J; Montaner, J; Soriano, E | 1 |
| Hanoglu, L; Kilic, E; Schabitz, WR; Yamaner, FY; Yulug, B | 1 |
| Dirnagl, U; Donnan, GA; Howells, DW; Macleod, MR; Sena, ES; van der Worp, HB | 1 |
| Benatar, M; Fisher, M; Philip, M; Savitz, SI | 1 |
| Arba, F; Balami, JS; Buchan, AM; Kleinschnitz, C; Minnerup, J; Sutherland, BA | 1 |
| Cheng, M; Kanakaraj, P; Kerr, I; Malaiyandi, L; Maples, KR; Siesjö, BK; Watson, JA; Ying Ma, J; Yoshimoto, T | 1 |
| Ashwood, T; Green, AR; Jackson, DM; Odergren, T | 1 |
| Jackson, DM; Sammut, IA | 1 |
| Ashwood, T; Green, AR | 1 |
| Ashwood, T; Campbell, M; Green, AR; Jonasson, H; Lanbeck-Vallén, K; Lindström Böö, E; Lundquist, S | 1 |
| del Zoppo, GJ | 1 |
| Ashwood, T; Davalos, A; Davis, SM; Diener, HC; Grotta, J; Hårdemark, HG; Lees, KR; Lyden, P; Shuaib, A; Wasiewski, WW; Zivin, JA | 1 |
| Hankey, GJ | 1 |
| Doggrell, SA | 1 |
| Fisher, M | 1 |
| Serebruany, V | 1 |
| Koziol, JA | 1 |
| Donnan, GA; Ly, JV; Zavala, JA | 1 |
| Feng, AC; Koziol, JA | 1 |
| Ashwood, T; Davalos, A; Davis, SM; Diener, HC; Emeribe, U; Grotta, J; Hardemark, HG; Lees, KR; Lyden, P; Shuaib, A; Wasiewski, W; Zivin, JA | 1 |
| Ginsberg, MD | 1 |
| Day, M; Feuerstein, GZ; Finklestein, SP; Krams, M; Pangalos, MN; Poole, M; Ruffolo, RR; Rutkowski, JL; Stiles, GL; Walsh, FL; Wang, X; Zaleska, MM | 1 |
| Ashwood, T; Davalos, A; Davis, SM; Diener, HC; Emeribe, U; Grotta, J; Lees, KR; Lyden, P; Shuaib, A; Wasiewski, WW | 1 |
| Bassetti, CL; Hermann, DM | 1 |
| Hori, O; Izuhara, Y; Kitao, Y; Miyata, T; Morita, Y; Ogawa, S; Takagi, S; Takizawa, S; van Ypersele de Strihou, C | 1 |
| Donnan, GA | 1 |
| Alderfer, V; Ashwood, T; Davalos, A; Davis, SM; Diener, HC; Grotta, J; Hårdemark, HG; Lees, KR; Lyden, P; Rodichok, L; Shuaib, A; Wasiewski, W | 1 |
| Chacon, MR; Jensen, MB; Sattin, JA; Zivin, JA | 1 |
| Duffin, KJ; Green, AR; Marshall, JW; Ridley, RM | 1 |
| Buchan, AM; Cheng, M; Ma, JY; Maples, KR; Zhao, Z | 1 |
| Borelli, AR; Cross, AJ; Green, AR; Sydserff, SG | 1 |
12 review(s) available for disufenton sodium and Brain Ischemia
| Article | Year |
|---|---|
Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality.
Topics: Animals; Benzenesulfonates; Bias; Brain Ischemia; Cardiovascular Agents; Clinical Trials as Topic; Research Design | 2008 |
Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials.
Topics: Acute Disease; Animals; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Humans; Neuroprotective Agents; Research; Research Design; Risk; Stroke | 2009 |
Neuroprotection for ischaemic stroke: translation from the bench to the bedside.
Topics: Acute Disease; Animals; Benzenesulfonates; Brain Ischemia; Chelating Agents; Clinical Trials as Topic; Combined Modality Therapy; Diffusion of Innovation; Disease Models, Animal; Drug Evaluation, Preclinical; Egtazic Acid; Hematopoietic Cell Growth Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothermia, Induced; Magnesium; Minocycline; NADPH Oxidases; Neuroprotective Agents; Pregnatrienes; Serum Albumin; Stroke; Thrombolytic Therapy; Translational Research, Biomedical | 2012 |
Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059.
Topics: Aged; Animals; Benzenesulfonates; Brain Ischemia; Humans; Middle Aged; Models, Cardiovascular; Neuroprotective Agents; Nitrogen Oxides; Stroke; Structure-Activity Relationship | 2003 |
Oxygen free radical traps for the treatment of ischemia-associated organ injury.
Topics: Animals; Benzenesulfonates; Brain Ischemia; Free Radical Scavengers; Free Radicals; Humans; Ischemia; Myocardial Ischemia; Myocardial Reperfusion Injury; Neuroprotective Agents; Nitrogen Oxides | 2004 |
Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers.
Topics: Animals; Antioxidants; Antipyrine; Azoles; Benzenesulfonates; Brain Ischemia; Edaravone; Free Radical Scavengers; Humans; Isoindoles; Mice; Mice, Mutant Strains; Neuroprotective Agents; Nitrogen Oxides; Organoselenium Compounds; Pregnatrienes; Rats; Reactive Oxygen Species; Stroke; Treatment Failure; Treatment Outcome | 2005 |
Is NXY-059 an advancement in the treatment of acute ischaemic stroke?
Topics: Acute Disease; Animals; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Humans; Nitrogen Oxides; Stroke | 2006 |
Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke.
Topics: Animals; Benzenesulfonates; Brain; Brain Ischemia; Drug Therapy, Combination; Fibrinolytic Agents; Free Radical Scavengers; GABA Agonists; Humans; Neuroprotective Agents; Nitrogen Oxides; Piperidines; Randomized Controlled Trials as Topic; Sodium Channel Blockers; Stroke; Thiazoles; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator | 2006 |
On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY-059 for acute ischemic stroke.
Topics: Acute Disease; Benzenesulfonates; Biomarkers; Brain Damage, Chronic; Brain Ischemia; Cardiovascular Agents; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Disability Evaluation; Double-Blind Method; Free Radical Scavengers; Humans; Neuroprotective Agents; Neuropsychological Tests; Nitrogen Oxides; Randomized Controlled Trials as Topic; Sample Size; Severity of Illness Index; Statistics, Nonparametric; Stroke; Treatment Failure; Treatment Outcome | 2006 |
Life after cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era.
Topics: Animals; Benzenesulfonates; Brain Ischemia; Drug Evaluation, Preclinical; Humans; Neuroprotective Agents; Stroke; Time Factors | 2007 |
Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke.
Topics: Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Approval; Drug Design; Drug Industry; Endpoint Determination; Guidelines as Topic; Humans; Models, Cardiovascular; National Institutes of Health (U.S.); Patient Selection; Stroke; Treatment Outcome; United States; United States Food and Drug Administration | 2008 |
Neuroprotection in cerebral ischemia: emphasis on the SAINT trial.
Topics: Acute Disease; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Clinical Trials as Topic; GABA Agonists; Humans; Hypothermia; N-Methylaspartate; Narcotic Antagonists; Neuroprotective Agents; Stroke; Tissue Plasminogen Activator | 2008 |
4 trial(s) available for disufenton sodium and Brain Ischemia
| Article | Year |
|---|---|
NXY-059 for acute ischemic stroke.
Topics: Acute Disease; Benzenesulfonates; Brain Ischemia; Cross-Over Studies; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Infusions, Intravenous; Nervous System Diseases; Neuroprotective Agents; Nitrogen Oxides; Severity of Illness Index; Stroke; Time Factors; Tissue Plasminogen Activator; Treatment Outcome | 2006 |
Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial.
Topics: Aged; Benzenesulfonates; Brain Ischemia; Double-Blind Method; Female; Humans; Male; Stroke; Treatment Outcome | 2006 |
NXY-059 for the treatment of acute ischemic stroke.
Topics: Acute Disease; Aged; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Odds Ratio; Stroke; Time Factors; Treatment Failure | 2007 |
NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials.
Topics: Age Factors; Aged; Antioxidants; Benzenesulfonates; Brain; Brain Ischemia; Cerebral Hemorrhage; Cerebral Infarction; Comorbidity; Double-Blind Method; Drug Administration Schedule; Emergency Medical Services; Encephalitis; Female; Humans; Hyperglycemia; Injections, Intravenous; Male; Meta-Analysis as Topic; Middle Aged; Neuroprotective Agents; Placebos; Prognosis; Stroke; Treatment Failure | 2008 |
16 other study(ies) available for disufenton sodium and Brain Ischemia
| Article | Year |
|---|---|
Nitrone derivatives of trolox as neuroprotective agents.
Topics: Animals; Antioxidants; Arterial Occlusive Diseases; Brain Ischemia; Cerebrovascular Circulation; Chromans; Free Radical Scavengers; Hydroxyl Radical; Infarction, Middle Cerebral Artery; Lipid Peroxidation; Mice; Neuroprotective Agents; Nitrogen Oxides; Structure-Activity Relationship | 2005 |
CholesteroNitrones for Stroke.
Topics: Animals; Antioxidants; Brain Ischemia; Cell Death; Cells, Cultured; Cholesterol; Ischemic Attack, Transient; Nervous System Diseases; Neurons; Neuroprotective Agents; Nitrogen Oxides; Rats; Reactive Oxygen Species; Reperfusion Injury; Stroke; Structure-Activity Relationship | 2015 |
Commentary : Hypothesis Focused Ultrasound and NXY-059 in Experimental Cerebral Ischemia: A New Therapeutic Opportunity?
Topics: Animals; Antioxidants; Benzenesulfonates; Brain Ischemia; Magnetic Resonance Imaging; RNA-Binding Protein FUS; Ultrasonic Therapy | 2016 |
NXY-059 maintains Akt activation and inhibits release of cytochrome C after focal cerebral ischemia.
Topics: Animals; Benzenesulfonates; Blotting, Western; Brain; Brain Ischemia; Cell Death; Cytochrome c Group; Down-Regulation; Immunohistochemistry; Male; Middle Cerebral Artery; Mitochondria; Neuroprotective Agents; Nitrogen Oxides; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Reperfusion Injury; Up-Regulation | 2002 |
Brain penetration of the novel free radical trapping neuroprotectant NXY-059 in rats subjected to permanent focal ischemia.
Topics: Animals; Antioxidants; Benzenesulfonates; Brain Ischemia; Cerebral Cortex; Free Radicals; Infusions, Intravenous; Nitrogen Oxides; Rats | 2006 |
Stroke and neurovascular protection.
Topics: Benzenesulfonates; Brain Ischemia; Humans; Nervous System Diseases; Neurons; Nitrogen Oxides; Stroke | 2006 |
Neuroprotection for acute ischaemic stroke: hope reignited.
Topics: Benzenesulfonates; Brain Infarction; Brain Ischemia; Humans; Meta-Analysis as Topic; Neuroprotective Agents; Nitrogen Oxides | 2006 |
The ischemic penumbra: a new opportunity for neuroprotection.
Topics: Animals; Benzenesulfonates; Brain; Brain Ischemia; Clinical Trials as Topic; Diffusion Magnetic Resonance Imaging; Drug Design; Humans; Magnetic Resonance Angiography; Neuroprotective Agents; Patient Selection; Recombinant Proteins; Stroke; Time Factors; Tissue Plasminogen Activator; Tomography, X-Ray Computed | 2006 |
NXY-059 for acute ischemic stroke.
Topics: Acute Disease; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Data Interpretation, Statistical; Hemorrhage; Humans; Nitrogen Oxides; Stroke | 2006 |
NXY-059 for acute ischemic stroke.
Topics: Acute Disease; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Data Interpretation, Statistical; Humans; Nitrogen Oxides; Stroke | 2006 |
Neuroprotection in the SAINT-II aftermath.
Topics: Benzenesulfonates; Brain Ischemia; Clinical Trials as Topic; Humans; Neuroprotective Agents; Spin Trapping; Stroke | 2007 |
A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia.
Topics: Animals; Antioxidants; Antipyrine; Benzenesulfonates; Blood Pressure; Brain Ischemia; Cell Death; Dose-Response Relationship, Drug; Edaravone; Endoplasmic Reticulum; Furans; Glycation End Products, Advanced; Immunohistochemistry; Indicators and Reagents; Infarction, Middle Cerebral Artery; Intracranial Thrombosis; Male; Mice; Mice, Knockout; Neuroprotective Agents; Oxidation-Reduction; Oxidative Stress; Protein Denaturation; Pyridines; Rats; Rats, Sprague-Dawley | 2007 |
The 2007 Feinberg lecture: a new road map for neuroprotection.
Topics: Animals; Benzenesulfonates; Brain Ischemia; Cardiovascular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Free Radical Scavengers; Humans; Neuroprotective Agents; Stroke | 2008 |
NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species.
Topics: Analysis of Variance; Animals; Arm; Behavior, Animal; Benzenesulfonates; Body Temperature; Brain; Brain Ischemia; Callithrix; Choice Behavior; Disease Models, Animal; Free Radical Scavengers; Hemodynamics; Infarction, Middle Cerebral Artery; Infusions, Intravenous; Kinesis; Motor Activity; Neuroprotective Agents; Nitrogen Oxides; Paresis; Perceptual Disorders | 2001 |
NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat.
Topics: Animals; Benzenesulfonates; Blood Pressure; Brain Ischemia; Cerebral Cortex; Cerebral Infarction; Cerebrovascular Circulation; Free Radical Scavengers; Free Radicals; Immunohistochemistry; Male; Microtubule-Associated Proteins; Nerve Degeneration; Neurons; Neuroprotective Agents; Nitrogen Oxides; Rats; Rats, Inbred SHR | 2001 |
Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window.
Topics: Administration, Cutaneous; Animals; Benzenesulfonates; Brain Ischemia; Cerebral Cortex; Cerebral Infarction; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Infarction, Middle Cerebral Artery; Infusion Pumps, Implantable; Ischemic Attack, Transient; Male; Neuroprotective Agents; Nitrogen Oxides; Rats; Rats, Inbred WKY | 2002 |